<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002312</url>
  </required_header>
  <id_info>
    <org_study_id>125A</org_study_id>
    <secondary_id>M/3331/0003</secondary_id>
    <nct_id>NCT00002312</nct_id>
  </id_info>
  <brief_title>The Safety and Effectiveness of U-90152 in HIV-1 Infected Patients Who Take Zidovudine</brief_title>
  <official_title>Open-Label Escalating Multiple-Dose Study of the Safety, Tolerance, and Pharmacokinetics of Oral U-90152 in HIV-1 Infected Males and Females With CD4 Counts of 200 - 500 Cells/mm3 Who Are Maintained on a Stable Dose of Zidovudine (AZT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmacia and Upjohn</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To evaluate the pharmacokinetics, safety, and tolerance of delavirdine mesylate ( U-90152 )&#xD;
      after multiple doses given orally to asymptomatic HIV-1 positive patients who are maintained&#xD;
      on a stable dose of zidovudine ( AZT ). To investigate the optimum dose regimen of U-90152&#xD;
      that gives average trough concentrations &gt; 1 micromolar in combination with standard AZT&#xD;
      therapy, and to examine drug interactions between the two drugs. To establish the MTD of&#xD;
      U-90152 in HIV-1 positive patients on stable AZT therapy. To investigate comparative&#xD;
      pharmacokinetics between HIV-1 positive men and women.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Delavirdine mesylate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Inhaled pentamidine following completion of the inpatient pharmacokinetic portion of&#xD;
             the study.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  HIV-1 infection.&#xD;
&#xD;
          -  CD4 count 200 - 500 cells/mm3.&#xD;
&#xD;
          -  Maintenance on AZT for at least 6 weeks.&#xD;
&#xD;
          -  No active opportunistic infections.&#xD;
&#xD;
          -  Ability to swallow numerous tablets without difficulty.&#xD;
&#xD;
          -  Ability to have blood samples drawn.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Acute medical problems, including opportunistic infections (such as active&#xD;
             cryptococcosis, pneumocystis carinii, herpes zoster, histoplasmosis, CMV) and&#xD;
             nonopportunistic diseases (liver and renal disease, orthostatic hypotension,&#xD;
             hypertension, progressive multifocal leukoencephalopathy, lymphoma, Kaposi's sarcoma,&#xD;
             or other malignancy).&#xD;
&#xD;
          -  Clinically significant hypersensitivity to piperazine type drugs (Antepar, Stelazine,&#xD;
             and U-87201E).&#xD;
&#xD;
          -  Negative EMIT drug screen or equivalent for drugs of abuse.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Antiretroviral agents other than AZT.&#xD;
&#xD;
          -  Primary or secondary prophylactic medications for opportunistic infections (inhaled&#xD;
             pentamidine is permitted following completion of the inpatient pharmacokinetic portion&#xD;
             of the study).&#xD;
&#xD;
        Patients with the following prior conditions are excluded:&#xD;
&#xD;
          -  History of clinically significant nervous system or muscle disease, seizure disorder,&#xD;
             AIDS dementia, or psychotic disorder that might impair study compliance.&#xD;
&#xD;
          -  History of clinically significant cardiovascular, renal, hepatic, cardiac, pulmonary,&#xD;
             endocrine, hematologic, vascular, or collagen disease.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Prior U-87201E or other non-nucleoside reverse transcriptase inhibitors (nevirapine,&#xD;
             TIBO, L-drugs, and HEPT).&#xD;
&#xD;
          -  Antiretroviral agents (other than AZT) or immunomodulating agents within 15 days prior&#xD;
             to study entry.&#xD;
&#xD;
          -  Primary prophylactic drugs within 15 days prior to study entry.&#xD;
&#xD;
          -  Any known enzyme-inducing drug or any enzyme-inhibiting agents, such as ketoconazole,&#xD;
             fluconazole, rifampin, isoniazid, and cimetidine, within 15 days prior to study entry.&#xD;
&#xD;
          -  Any investigational medication within 15 days prior to study entry. Unwilling to&#xD;
             comply with safer sex practices. Active substance abuse. Alcohol consumption during&#xD;
             the inpatient pharmacokinetic portion of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Bronson Methodist Hosp / Upjohn Research Clinic</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>490074949</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Batts DH, Freimuth WW, Cox SR, Peel BG, Hanover CK, Wathen LK, Staton BA. Open-label escalating multiple-dose study of the safety,tolerance, and pharmacokinetics of oral U-90152S (delavirdine, DLV) in HIV-1 infected males and females with CD4 counts of 200 to 500/mm3, who are maintained on a stable dose of AZT. Natl Conf Hum Retroviruses Relat Infect (1st). 1993 Dec 12-16:158</citation>
  </reference>
  <verification_date>April 1994</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Drug Interactions</keyword>
  <keyword>Antiviral Agents</keyword>
  <keyword>Zidovudine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Delavirdine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

